February 4 - 9, 2027 at The Royal Sonesta Kaua'i Resort Lihue

Agenda

Thursday, February 4

  • 6:00 AM - Continental Breakfast/Introductions and Welcome (S. DeMeester and S. Spechler)

SESSION 1: GERD and Esophageal Diagnostics (Moderator: Guilherme Campos)

  • 6:45 AM - The spectrum of GERD and global distribution (S. Spechler)

  • 7:30 AM - GERD evaluation: options and when to use them (P. Katz)

  • 8:15 AM - If I was... (20 minutes each)

    • a surgeon, how would I manage my GERD patients? (J. Pandolfino)

    • a GI, how would I manage my GERD patients? (S. DeMeester)

  • 9:15 AM - Pathogenesis of GERD, cardiac mucosa and intestinal metaplasia (R. Souza)

  • 10:15 AM - Coffee Break/Case Presentations

  • 10:30 AM - EGD in the evaluation and follow-up of bariatric surgery patients (O. Old)

  • 11:15 AM - Global burden of foregut IM and adenocarcinoma (H. El-Serag)

SESSION 2: Barrett’s I — Lunch Provided (Moderator: Steve DeMeester)

  • 12:15 PM - Pitfalls in the pathologic diagnosis of dysplasia and early EAC (P. Chandrasoma)

  • 1:00 PM - Cellular and molecular etiology of foregut IM and biomarkers for detection and risk stratification (R. Fitzgerald)

  • 2:00 PM - Adjourn

  • 2:45 PM - Hands On Sessions (TBD)

  • 4:00 PM - Adjourn

  • 5:30 PM - Welcome Reception - All Participants

Friday, February 5

SESSION 3: Barrett’s II (Moderator: Stu Spechler)

  • 6:00 AM - Industry Break the Fast with Science

  • 7:00 AM - Natural history of CIM and short-segment BE (H. El-Serag)

  • 7:45 AM - What is BE in 2027 and should the definition be changed (S. Komonduri)

  • 8:30 AM - Antireflux surgery in patients with BE: Indications, outcomes and impact on the natural history of the disease (O. Old)

  • 9:15 AM - Options and outcomes in BE patients with obesity (G. Campos)

  • 10:00 AM - Extended Coffee Break/Case Presentations (snack)

SESSION 4: Endoscopic management of dysplasia and EAC

  • 10:45 AM - Can endoscopic therapy change the natural history of BE? What the trials and data tell us (N. Shahin)

  • 11:30 AM - Management of HGD and T1 adenocarcinoma (20 minutes each):

    • Dutch strategy and data (R. Pouw)

    • US strategy and data (F. Schnoll-Sussman)

  • 12:25 PM - Pulling back the curtain: Surgical management of failed endotherapy (20 minutes each):

    • Dutch data and patient selection for esophagectomy (R. van Hillegersberg)

    • MSK experience and pattern of recurrence after surgery (D. Molena)

  • 1:20 PM - Adjourn

Saturday, February 6

  • 6:00 AM - Industry Break the Fast with Science/Case Presentation

SESSION 5: Esophageal Potpourri (Moderator: Daniela Molena)

  • 7:00 AM - The EOE epidemic: Drivers and how to manage the disease (D. Katzka)

  • 7:45 AM - Secrets to getting the most out of HRM and FLIP (J. Pandolfino)

  • 8:30 AM - Breakout Rooms

  • 10:30 AM - Coffee Break/Case Presentations

  • 10:45 AM - Jo Skibby Lecture

  • 11:45 AM - Who, why and how: PEH repair in 2027 (S. DeMeester)

  • 12:30 PM - Adjourn

  • 3:30 PM - Cocktails with the Faculty

Sunday, February 7 – Free Day

Monday, February 8

  • 6:30 AM - Continental Breakfast/Case Presentations

SESSION 6: CME BE Screening and Surveillance (Moderator: Felice Schnoll-Sussman)

  • 6:30 AM - Continental Breakfast/Case Presentations

  • 7:00 AM - Screening and surveillance for BE: How did we get to where we are? (S. DeMeester)

  • 7:45 AM - Screening and surveillance for BE: who, how and the promise and limitations of current non-endoscopic options (R. Fitzgerald)

  • 8:30 AM - Surveillance and the BOSS trial (O. Old)

  • 9:15 AM - Keys to moving the surveillance needle forward (S. Spechler)

  • 10:15 AM - Coffee Break/Case Presentations (snack)

SESSION: 7 BE Surveillance and endotherapy

  • 10:30 AM - Missed lesions: how often and what are the consequences (D. Katzka)

  • 11:15 AM - Can we improve surveillance: AI, p-CLE, Tissue Cypher and other technologies? (R. Pouw)

  • 12:00 PM - Who, when and how to intervene in BE (N. Shaheen)

  • 12:45 PM - How and for how long: surveillance after endoscopic therapy (F. Schnoll-Sussman)

  • 1:30 PM - Adjourn

  • 6:30 PM - Course Reception

Tuesday, February 9

  • 6:30 AM - Continental Breakfast/Case Presentations

SESSION 8: CME BE and endotherapy (Moderator: Stu Spechler)

  • 7:00 AM - Etiology and significance of buried Barrett's (R. Souza)

  • 7:45 AM - Cost-effectiveness for BE screening and surveillance (H. El-Serag)

  • 8:30 AM - Management of residual or recurrent disease during/after EET (R. Pouw)

  • 9:15 AM - IM at the GEJ after ablation: what is it and does it matter (N. Shaheen)

  • 10:15 AM - Coffee Break/Case Presentations

SESSION 9: CME Esophageal Adenocarcinoma (Moderator: Steve DeMeester)

  • 10:30 AM - Managing complications of endotherapy (S. Komonduri)

  • 11:15 AM - Is esophagectomy necessary after neoadjuvant therapy and what approach gives the best outcomes (R. van Hillegersberg)

  • 12:00 PM - How do we improve survival in ≥ T2 adenocarcinoma? (D. Molena)

  • 12:45 PM - Adjourn